David L Veenstra

Summary

Publications

  1. ncbi request reprint Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT)
    William J Canestaro
    University of Washington, H375 HSB Box 357630, 1959 N E Pacific St, Seattle, WA 98195 7630
    J Manag Care Spec Pharm 21:700-12. 2015
  2. pmc Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update
    David L Veenstra
    Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, Institute for Public Health Genetics, University of Washington, Seattle, Washington, USA
    Genet Med 15:14-24. 2013
  3. pmc Stakeholder perspectives on a risk-benefit framework for genetic testing
    Joshua A Roth
    Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Public Health Genomics 14:59-67. 2011
  4. pmc Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics
    Josh J Carlson
    Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Med Decis Making 33:463-71. 2013
  5. pmc A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke
    Denise M Boudreau
    University of Washington, Seattle, WA, USA
    Ann Emerg Med 61:46-55. 2013
  6. doi request reprint The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
    Josh J Carlson
    School of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Value Health 12:20-7. 2009
  7. pmc The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)
    William B Wong
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
    Contemp Clin Trials 33:1117-23. 2012
  8. doi request reprint Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer
    Josh J Carlson
    University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA
    J Med Econ 14:159-66. 2011
  9. pmc Estimating the costs of induced abortion in Uganda: a model-based analysis
    Joseph B Babigumira
    Global Medicines Program, Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA
    BMC Public Health 11:904. 2011
  10. pmc Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis
    Rahber Thariani
    Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    J Comp Eff Res 2:325-34. 2013

Collaborators

Detail Information

Publications37

  1. ncbi request reprint Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT)
    William J Canestaro
    University of Washington, H375 HSB Box 357630, 1959 N E Pacific St, Seattle, WA 98195 7630
    J Manag Care Spec Pharm 21:700-12. 2015
    ..Although CDTs can offer a multitude of potential benefits, assessing their value within a health technology appraisal process can be challenging because of a complex array of factors that influence clinical and economic outcomes...
  2. pmc Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update
    David L Veenstra
    Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, Institute for Public Health Genetics, University of Washington, Seattle, Washington, USA
    Genet Med 15:14-24. 2013
    ..The rapid advances in genomics present a significant challenge to traditional evidence based medicine, but also an opportunity for innovative approaches to recommendation development...
  3. pmc Stakeholder perspectives on a risk-benefit framework for genetic testing
    Joshua A Roth
    Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Public Health Genomics 14:59-67. 2011
    ..The meeting's findings emphasize the potential utility of risk-benefit analysis in genetic test evaluation, and highlight key areas for future research and stakeholder consensus-building...
  4. pmc Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics
    Josh J Carlson
    Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Med Decis Making 33:463-71. 2013
    ..The objective of this study was to evaluate the feasibility and outcomes of incorporating value-of-information (VOI) analysis into a stakeholder-driven research prioritization process in a US-based setting...
  5. pmc A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke
    Denise M Boudreau
    University of Washington, Seattle, WA, USA
    Ann Emerg Med 61:46-55. 2013
    ..We evaluate the long-term incremental cost-effectiveness of rtPA administered 3 to 4.5 hours after acute ischemic stroke onset versus no treatment according to patient clinical and demographic factors...
  6. doi request reprint The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
    Josh J Carlson
    School of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Value Health 12:20-7. 2009
    ..The objective of this study was to evaluate the potential cost-utility of implementing epidermal growth factor receptor (EGFR) testing before initiating second-line therapy for advanced refractory non-small-cell lung cancer (NSCLC)...
  7. pmc The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)
    William B Wong
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
    Contemp Clin Trials 33:1117-23. 2012
    ..The objective of this study was to assess the value of research of the RxPONDER study, an ongoing comparative effectiveness RCT designed to evaluate a 21-gene profile in early stage, node-positive breast cancer...
  8. doi request reprint Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer
    Josh J Carlson
    University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA
    J Med Econ 14:159-66. 2011
    ..Assess the budgetary impact of adding erlotinib for maintenance therapy (MTx) in advanced non-small cell lung cancer (NSCLC) from a US health plan perspective...
  9. pmc Estimating the costs of induced abortion in Uganda: a model-based analysis
    Joseph B Babigumira
    Global Medicines Program, Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA
    BMC Public Health 11:904. 2011
    ..These abortions, which are usually unsafe, lead to a high rate of severe complications and use of substantial, scarce healthcare resources. This study was performed to estimate the costs associated with induced abortions in Uganda...
  10. pmc Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis
    Rahber Thariani
    Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    J Comp Eff Res 2:325-34. 2013
    ..Breast cancer tumor markers are used by some clinicians to screen for disease recurrence risk. Since there is limited evidence of benefit, additional research may be warranted...
  11. pmc Paying for personalized care: cancer biomarkers and comparative effectiveness
    Rahber Thariani
    Department of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
    Mol Oncol 6:260-6. 2012
    ..Evidence of comparative effectiveness can also help support value-based reimbursement of cancer biomarkers and treatment strategies as means of paying for personalized medicine...
  12. pmc Prioritization in comparative effectiveness research: the CANCERGEN Experience
    Rahber Thariani
    Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Med Care 50:388-93. 2012
    ..Genomic testing in cancer is an ideal area to refine such approaches given rapid innovation and potentially significant impacts on patient outcomes...
  13. pmc Tumor marker usage and medical care costs among older early-stage breast cancer survivors
    Scott D Ramsey
    Scott D Ramsey, Julie R Gralow, Dana K Mirick, William Barlow, Ruth Etzioni, and David Mummy, Fred Hutchinson Cancer Research Center Scott D Ramsey, Julie R Gralow, Rahber Thariani, and David L Veenstra, University of Washington, Seattle, WA and N Lynn Henry, University of Michigan, Ann Arbor, MI
    J Clin Oncol 33:149-55. 2015
    ..Our objective was to determine use of tumor marker tests such as carcinoembryonic antigen and CA 15-3/CA 27.29 and associated Medicare costs in early-stage breast cancer survivors...
  14. ncbi request reprint Design, implementation, and first-year outcomes of a value-based drug formulary
    Sean D Sullivan
    University of Washington, 1959 N E Pacific Ave, Seattle, WA 98196
    J Manag Care Spec Pharm 21:269-75. 2015
    ..Concurrently, Premera increased copayments for existing tiers...
  15. pmc Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation
    David H Salinger
    Department of Bioengineering, University of Washington, Seattle, Washington, USA
    Pharmacogenet Genomics 19:965-71. 2009
    ..The objective of this study was to explore the incremental effect of pharmacogenomic-guided warfarin dosing under various conditions using clinical trial simulation...
  16. pmc Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model
    Kelley R Branch
    Division of Cardiology, University of Washington, Seattle, 98195, USA
    Acad Radiol 19:265-73. 2012
    ..The objective of this study was to compare the cost of CCT-based evaluation versus standard of care (SOC) using the results of a clinical trial...
  17. doi request reprint Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy
    Gregory F Guzauskas
    Center for Genomics and Healthcare Equality, University of Washington, Seattle, Washington, USA
    Genet Med 15:84-7. 2013
    ..We evaluated genetic services stakeholder opinions on the potential usefulness of decision-analytic modeling to inform coverage decisions, and asked them to identify genetic tests for decision-analytic modeling studies...
  18. ncbi request reprint Systematic review of comparative effectiveness data for oncology orphan drugs
    Mindy M Cheng
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    Am J Manag Care 18:47-62. 2012
    ..To systematically assess clinical and economic evidence for oncology orphan drugs marketed in the United States and to highlight the challenges and opportunities for evidence development within this pharmaceutical category...
  19. doi request reprint A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics
    Preeti S Bajaj
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
    Genet Med 15:374-81. 2013
    ..We sought to assess the benefits, risks, and personal utility of factor V Leiden mutation testing to improve pregnancy outcomes and to assess the utility of decision-analytic modeling for complex outcomes in genomics...
  20. pmc Navigational bronchoscopy with biopsy versus computed tomography-guided biopsy for the diagnosis of a solitary pulmonary nodule: a cost-consequences analysis
    Christopher R Dale
    Division of Pulmonary and Critical Care Medicine, Harborview Medical Center, University of Washington, Seattle, WA 98104, USA
    J Bronchology Interv Pulmonol 19:294-303. 2012
    ..A nondiagnostic computed tomography (CT)-guided or ENB biopsy is often followed by video-assisted thoracoscopic surgery (VATS) biopsy. The relative costs and consequences of these strategies are not known...
  21. pmc Potential cost-effectiveness of universal access to modern contraceptives in Uganda
    Joseph B Babigumira
    Global Medicines Program, Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 7:e30735. 2012
    ....
  22. pmc Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT)
    Caroline Savage Bennette
    Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
    Genet Med 15:873-81. 2013
    ..This study identified attributes of incidental findings that were important to patients and developed a discrete-choice experiment instrument to quantify patient preferences...
  23. doi request reprint The cost-effectiveness of returning incidental findings from next-generation genomic sequencing
    Caroline S Bennette
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
    Genet Med 17:587-95. 2015
    ..Our objective was to evaluate the clinical and economic impact of returning these results...
  24. doi request reprint Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis
    Preeti S Bajaj
    University of Washington, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, Seattle, WA 98195, USA
    J Med Econ 17:538-46. 2014
    ..This study sought to estimate the budget impact if coverage for EGFR testing and erlotinib as first-line therapy were provided in a hypothetical 500,000-member managed care plan...
  25. doi request reprint Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195 7630, United States
    Health Policy 96:179-90. 2010
    ..To identify, categorize and examine performance-based health outcomes reimbursement schemes for medical technology...
  26. doi request reprint Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination
    Louis P Garrison
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    J Infect Dis 204:S124-32. 2011
    ..Funders need to prioritize their scarce research and development resources. This article demonstrates the usefulness of cost-effectiveness analysis to support these decisions...
  27. doi request reprint A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia
    Mindy M Cheng
    University of Washington, Department of Pharmacy, Box 357630, Seattle, WA 98195 7630, USA
    Cancer Treat Rev 38:1004-11. 2012
    ..Many of these therapies have been compared against chlorambucil, but have not been directly compared against each other. There is currently no agreed upon standard therapeutic regimen for treatment-naïve CLL...
  28. doi request reprint The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer
    Louis P Garrison
    Department of Pharmacy, University of Washington, Health Sciences Building, Seattle, WA 98195 7630, USA
    Value Health 12:1118-23. 2009
    ....
  29. doi request reprint Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting
    Joshua A Roth
    Group Health Research Institute, Group Health, Seattle, WA, USA
    Pharmacoepidemiol Drug Saf 24:619-27. 2015
    ..We conducted a case-control study to assess the association between screening positive for moderate/severe alcohol misuse and the risk of major bleeding in a community sample of patients using warfarin...
  30. doi request reprint Cost effectiveness of pharmacogenomics: a critical and systematic review
    William B Wong
    University of Washington, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, Seattle, Washington 98195 7630, USA
    Pharmacoeconomics 28:1001-13. 2010
    ..Despite a recent increase in the number of economic evaluations of pharmacogenetic applications, further studies examining the clinical validity and utility of these biomarkers are needed to support cost-effectiveness assessments...
  31. pmc Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support
    Casey Lynnette Overby
    Department of Medical Education and Biomedical Informatics, University of Washington, Seattle, WA, USA
    BMC Bioinformatics 11:S10. 2010
    ..g. IF age <18 THEN patient is a child), sufficient clinical data exists in University of Washington's EMR systems to support 50% of PGx knowledge contained in drug labels that could be expressed as rules...
  32. pmc CDR state transition probabilities in Alzheimer's disease with and without cholinesterase inhibitor intervention in an observational cohort
    Lisa M Bloudek
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    J Alzheimers Dis 24:599-607. 2011
    ..The NACC-UDS dataset is ongoing and this analysis may be improved if repeated when more data is available...
  33. pmc Long-term survival in patients with severe acute respiratory distress syndrome and rescue therapies for refractory hypoxemia*
    Nita Khandelwal
    1Department of Anesthesiology and Pain Medicine, University of Washington, Harborview Medical Center, Seattle, WA 2Division of Pulmonary and Critical Care Medicine, University of Washington, Harborview Medical Center, Seattle, WA 3Department of Biostatistics, University of Washington, Seattle, WA 4Department of Pharmacy, University of Washington, Seattle, WA 5Department of Epidemiology, University of Washington, Seattle, WA
    Crit Care Med 42:1610-8. 2014
    ....
  34. doi request reprint The cost-effectiveness of primary stroke centers for acute stroke care
    Gregory F Guzauskas
    University of Washington, Seattle, WA 98195, USA
    Stroke 43:1617-23. 2012
    ..The objective of this study was to evaluate the cost-effectiveness of treating AIS patients in a PSC compared with a nonPSC hospital setting...
  35. doi request reprint Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis
    Marc Blondon
    Department of Internal Medicine, School of Public Health, University of Washington, Seattle, WA 98195, USA
    Chest 141:321-9. 2012
    ..The cost-effectiveness of this treatment remains to be determined...
  36. doi request reprint The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment
    Mindy M Cheng
    University of Washington, Seattle, WA 98195, USA
    J Med Econ 13:193-202. 2010
    ..To critically evaluate published cost-effectiveness studies of novel drug products requiring less-frequent medication dosing compared to conventional formulations of the same drug substance...
  37. pmc A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice
    David L Veenstra
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Genet Med 12:686-93. 2010
    ..To address these issues, this study presents a risk-benefit framework for assessing the health-related utility of genomic tests...